Position in RPRX
as of Sep 30, 2026
· filed Oct 6, 2026
Position Value
$30,761,205
New position
Shares Held
527,094
first reported quarter
Ownership
0.092%
of shares outstanding
% of Portfolio
0.20%
of 13F equity value
Holder Rank
#2
of 9 holders
Holding Since
Sep 2026
1 quarter on record
Voting authority
Sole 78%
Shared 11%
None 11%
Position in Biotechnology
Healthcare · as of Sep 30, 2026CONGRESS ASSET MANAGEMENT CO holds $800,491,000 across 14 Biotechnology names. RPRX ranks #5 (3.8% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | HALO |
Halozyme Therapeutics, Inc.
|
2,281,615 | $251,890,296 | |
| 2 | LGND |
Ligand Pharmaceuticals Inc
|
658,556 | $205,713,137 | |
| 3 | TGTX |
Tg Therapeutics, Inc.
|
2,606,516 | $145,391,462 | |
| 4 | VCEL |
Vericel Corp
|
2,552,066 | $102,439,929 | |
| 5 | RPRX |
Royalty Pharma plc
This page
|
527,094 | $30,761,205 | |
| 6 | KRYS |
Krystal Biotech, Inc.
|
54,083 | $17,985,842 | |
| 7 | RLAY |
Relay Therapeutics, Inc.
|
779,544 | $14,070,769 | |
| 8 | TNGX |
Tango Therapeutics, Inc.
|
478,454 | $11,937,427 |
All Filings in RPRX
Export CSV
1 filing row on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-09-30 | $30,761,205 | 527,094 | Shares | Sole | 2026-10-06 | |
| No filing history on record for this holder in this stock. | ||||||